Capnocytophaga species have been associated with a wide variety of infections in both immunocompetent and immunocompromised patients. On the basis of data from antimicrobial susceptibility studies, beta-lactam antibiotics have been considered efficacious therapy. Six of 19 isolates from primarily clinical sources across Canada demonstrated ,-lactamase production, and agar dilution susceptibility testing showed broad resistance to beta-lactam antibiotics. For the P-lactamase producing isolates, clavulanate reduced the MIC of amoxicillin for 90% of the strains tested by 64-fold. Isolates were highly susceptible to clindamycin, imipenem, and ciprofloxacin. Characterization of the 13-lactamases produced by two of these isolates (Vanl and Van2) was performed. Isoelectric focusing revealed an identical isoelectric point of 5.6 for both enzymes, but they had markedly different relative hydrolysis efficiencies, and different conditions were required to extract the enzymes. This study demonstrates the production of different types of 13-lactamases by Capnocytophaga spp. and suggests the need to screen all clinical isolates of Capnocytophaga spp. for the presence of 13-lactamases.
Capnocytophaga species are part of the normal oral flora of humans and animals and have been implicated in the polymicrobial etiology of gingivitis and localized periodontitis (25) . Systemic infections were first reported for immunocompromised hosts, usually in association with severe chemotherapy-induced oral ulcerations (1, 10, 12) . Subsequently, Capnocytophaga spp. were recognized as the cause of a variety of infections in the immunocompetent host, including bacteremia (28) , endocarditis (7), mediastinal abscess (24) , septic arthritis (34) , peritonitis (23) , pyonephrosis (33) , inguinal lymphadenopathy (17) , necrotizing keratitis (15, 29) , and a number of peripartum infections leading to chorioamnionitis, prematurity, and sepsis in the newborn (8, 13, 21, 22) . Therapy of these infections is often empiric and it is therefore important to know which antibiotics are predictably active against Capnocytophaga spp. Five major studies of the antimicrobial susceptibility of Capnocytophaga spp. have shown that these organisms are typically susceptible to penicillin, clindamycin, chloramphenicol, the quinolones, and expanded-spectrum cephalosporins, while susceptibility to narrow-spectrum cephalosporins is variable (2, 9, 14, 30, 32) . Only 4 of the 287 strains described in these studies produced a 1-lactamase (2, 30) , and septicemia due to ,-lactamase-producing Capnocytophaga spp. was not reported until 1987 (3). Consequently, the isolation of ,-lactamase-producing Capnocytophaga spp. from two different patients with neutropenic sepsis at the teaching hospitals of the University of British Columbia caused concern and prompted this investigation into the antibiotic susceptibility of Capnocytophaga spp. in Canada.
( (20) . As this method proved to be unsuitable for detection of Van2, both enzymes were also focused in a 4% Sephadex gel slurry, with the addition of 3% ampholine and 4% Triton-X. Electrofocusing was carried out on a watercooled flat-bed apparatus, with a connected high-voltage power supply (Multiphor System-LKB; Pharmacia, Uppsala, Sweden). Standard enzymes of known pI, as well as commercial isoelectric point markers (BDH, Darmstadt, Germany), were used.
(iii) Hydrolysis studies. Hydrolysis studies were carried out in a temperature-controlled spectrophotometer at 37°C as previously described (35) . The reported kinetic constants were derived from half-time analysis of single-reaction progress curves (27) .
RESULTS All 19 isolates were tested for t-lactamase production by the nitrocefin test, and 6 gave positive results. Only one, Vanl, gave a rapid reaction, turning dark pink within seconds. The other isolates developed a positive reaction more slowly, but all were positive within 5 min. The tests were observed for a total of 30 min before isolates were called negative. Table 1 shows that the non-,B-lactamase-producing strains were sensitive to all the beta-lactams tested, whereas the 3-lactamase-producing strains were highly resistant to penicillin and amoxicillin. The addition of 1 ,ug of clavulanate per ml to amoxicillin resulted in a 64-fold lowering of the MIC for 90% of the ,B-lactamase-producing isolates (MIC90) and a lowering of the amoxicillin geometric mean MIC for all strains from 3.7 to 0.17 ,ug/ml. Results with the cephalosporins were more variable. The ,B-lactamase-producing isolates were highly resistant to cefazolin and were more resistant to cefuroxime, cefotaxime, and ceftazidime than non-1-lactamase-producing strains. 3-Lactamase-producing and non-3-lactamase-producing strains were equally sensitive to imipenem. MICgs of the non-beta-lactam antibiotics for all isolates indicated susceptibility to clindamycin and ciprofloxacin, resistance to gentamicin, and variable susceptibility to vancomycin and metronidazole.
Kinetic data for the enzymes from isolates Vanl and Van2 are shown in Table 2 . Enzyme yields from Van2 were negligible without the addition of Triton-X. Although the MICs for the beta-lactam antibiotics, with the exception of cefoxitin and ceftazidime, were shown to be similar for Vanl and Van2 and although both produce an enzyme with an isoelectric point of 5.6, the substrate profiles of Vanl and Van2 are different. Compared with the activity against cephaloridine, the enzyme from Van2 was shown to be inefficient at hydrolyzing the other cephalosporins and penicillins. However, Vanl was shown to be efficient at hydrolyzing a wide range of beta-lactams, including the extendedspectrum cephalosporins. 
DISCUSSION
The genus Capnocytophaga as described in 1979 incorporates the organisms formerly known as Bacteroides ochraceus and CDC group DF-1 and includes three species (C. ochracea, C. sputigena, and C. gingivalis) (19, 26) . Distinguishing between the species is difficult, and the clinical significance of species differentiation is not known. In 1989, C canimorsus (formerly CDC group DF-2) and C. cynodegmi (CDC group DF-2-like) were proposed as two new species in this genus (6) . Previous antimicrobial susceptibility studies have included the first three named species and have shown predictable susceptibility to beta-lactam antibiotics, clindamycin, and the quinolone antibiotics; variable susceptibility to metronidazole; and fairly uniform resistance to aminoglycosides and vancomycin. There are very few reports on the susceptibility patterns of the newer additions to the genus, but the limited data available suggest similar susceptibility patterns (5, 16) .
The results of this study support initial observations of others that ,-lactamase production is becoming more common in Capnocytophaga spp. (3, 4, 18, 30 Many infections with Capnocytophaga spp. occur in immunocompromised patients, which heightens the significance of identifying ,3-lactamase production in this genus. As noted by others (4) , empiric therapy in the febrile neutropenic host may not cover P-lactamase-producing Capnocytophaga spp. Clinicians may need to consider this possibility, particularly in the immunocompromised patient with severe oral mucositis or periodontal disease or in the patient who is not responding to conventional therapy.
In summary, ,-lactamase production by Capnocytophaga spp. may be more common than previously realized. All clinical isolates should be tested for ,B-lactamase production, and clinicians should be aware that standard empiric therapy for febrile neutropenic patients may not cover 3-lactamaseproducing Capnocytophaga spp. Further studies are necessary to characterize the different ,-lactamases which are present.
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